The in vitro interactions between amikacin, netilmicin, tobramycin, gentamicin, and various antipseudomonal P-lactams were studied by the agar dilution checkerboard technique against 30 Pseudomonas aeruginosa strains resistant to all tested antibiotics. Amikacin produced more frequent synergy both at the total and clinically applicable level. Among the P-lactams, clinically relevant synergistic interactions were obtained in the following order: ceftazidime and ceftriaxone > moxalactam > aztreonam > cefotaxime > azlocillin > cefoperazone > cefsulodin > carbenicillin.
Pseudomonas aeruginosa infections, particularly in patients with reduced immunocompetence, are frequent causes of morbidity and mortality in a hospital setting (3) . The use of antibiotic combinations that have been proved to be synergistic in vitro is associated with a significantly better in vivo response (6) (7) (8) , particularly in the compromised host in which the traditional treatment combines an antipseudomonal penicillin with an aminoglycoside. Combinations with new ,B-lactams that do not possess definite bactericidal antipseudomonal activity (4) constitute an alternative in the treatment of these infections, particularly whenever multiresistant strains are concerned (12, 14 ,ug/ml; azlocillin; >64 ,ug/ml; carbenicillin, >128 ,ug/ml).
They represented clinical isolates derived between January and July 1983 from patients suffering from septicemia, urinary tract infection, pneumonia, and wound suppuration.
The MICs for the P. aeruginosa strains were determined by agar dilution and confirmed by the broth dilution technique. Twofold dilutions of antibiotics from 512 to 0.5 ,ug/ml were added to Mueller-Hinton broth ( Interaction studies were performed by the checkerboard agar dilution method (9) . Serial twofold dilutions of antibiotic over the range of 256 to 0.5 ,ug/ml were used. A combina-* Corresponding author. tion was defined as synergistic if one-quarter or less of the MIC of each drug, when used separately, produced inhibition of bacterial growth when combined (9) . However, synergism was considered as clinically relevant whenever the MIC of each antibiotic in the combination did not exceed mean serum levels achievable in humans: gentamicin, tobramycin, and netilmicin, 8 jig/ml; amikacin, 16 pug/ml; cephalosporins and aztreonam, 32 ,uglml; azlocillin, 64 ,ug/ml; and carbenicillin, 128 jig/ml.
For two Pseudomonas strains, for which synergistic interaction with the amikacin-13-lactam combination has been proved by the checkerboard method, bacterial killing studies were also carried out to measure changes over time. However, the traditional combination of one-quarter the MIC was not applied, because results based on the very high MICs could not have clinical relevance. Instead, killing studies were performed in Mueller-Hinton broth containing the above-mentioned concentrations representing the mean achievable levels in serum when these antibiotics are administered by conventional treatment schedules. Exponentionally growing cultures of P. aeruginosa were diluted with fresh Mueller-Hinton broth to 10' CFU/ml. Samples were removed at time zero and after 2, 4, 6, and 24 h of incubation. They were then immediately plated at multiple dilutions on MacConkey agar to determine viable cell counts. Synergism was defined as .100-fold increased killing at 24 h by both drugs as compared with the single most effective drug alone (9) . Results were statistically evaluated by the x2 test (Yate's correction).
For the P. aeruginosa strains studied, the MICs for 50% of the organisms were as follows: amikacin, 128 ,ug/ml; other aminoglycosides, 512 ,ug/ml; ceftazidime, 64 ,ug/ml; cefotaxime, moxalactam, and aztreonam, 128 jig/ml; and the other P-lactams, 512 ,g/ml. The corresponding MIC for 90% of the organisms of amikacin, ceftazidime, and aztreonam was 256 ,ug/ml, whereas for the other aminoglycosides and ,-lactams it was >512 ,ug/ml.
The in vitro results of interactions between the aminoglycosides and the ,B-lactams are presented in Table 1 . Amikacin produced more frequent synergistic interactions. When compared with tobramycin, amikacin was statistically significantly more synergistic with cefsulodin (P < 0.001), cefotaxime (P < 0.01), and ceftriaxone (P < 0.02). Statistically significantly higher synergy with amikacin, compared with netilmicin and gentamicin, was demonstrated when combined with azlocillin (P < 0.05) and cefsulodin (P < 0.001). Both gentamicin and netilmicin demonstrated significantly higher synergistic activity, compared with tobramycin, when combined with'cefotaxime (P < 0.01). Tobramycin obtained better synergistic activity, compared with gentamicin, when combined with cefoperazone (P < 0.01). Netilmicin, compared with tobramycin, produced better synergistic activity when combined with ceftriaxone (P < 0.05). No statistically significant differences were observed between the synergistic activity of gentamicin, when combined with thelactams, and netilmicin. Clinically relevant synergistic interaction was also demonstrated significantly more often with amikacin. When compared with gentamicin combinations, amikacin statistically significantly produced more frequent clinically relevant synergy when-combined with azlocillin (P = 0.05), cefsulodin (P < 0.05), cefotaxime (P < 0.01), ceftriaxone (P < 0.001), ceftazidime (P < 0.05), and moxalactam (P < 0.05). Compared with netilmicin, amikacin combinations with azlocillin (P = 0.05), cefsulodin (P < 0,01), ceftriaxone (P < 0.01), and moxalactam (P < 0.05) were evaluated as clinically more relevant. Finally, compared with tobramycin-p-lactam com- binations, clinically relevant synergy was obtained more frequently when amikacin was combined with cefotaxime (P < 0.01) and ceftriaxone (P < 0.001). Differences between the combinations of 1-lactams and other aminoglycosides were not statistically significant. However, it should be pointed out that more frequent clirnically applicable synergy was obtained when ceftazidime, with the lowest MIC levels, was combined with the aminoglycosides. The bactericidal effect over time is presented in Fig. 1 . Successful synergistic interactions with amikacin produced a bactericidal effect as early as 2 h and no later than 6 h. The combination of tobramycin, netilmicin, or gentamicin with the ,3-lactams allowed growth equal to that of the control.
Information on the interactions between aminoglycosides and recently introduced P-lactams is limited. Kurtz et al. (10) have reported significant in vitro synergistic'antibacterial activity against many P. aeruginosa and Serratia marcescens isolates when amikacin was combined with moxalactam, cefoperazone, or cefotaxime. Successful synergistic interactions between amikacin and either azlocillin or cefotaxime against gram-negative bacteria and Staphylococcus aureus have also been achieved both in vitro (2, 3, 5, 15) and in vivo in the neuropenic mouse model and in human volunteers (2, 17) . On the other hand, unsatisfactory and unpredictable synergistic interactions against both resistant and susceptible P. aeruginosa strains with combinations of tobramycin or gentamicin with cefotaxime, moxalactam, and cefoperazone have been reported (13, 16) . The better synergistic results observed in this study with amikacin should be attributed to the inactivation of amikacin by fewer aminoglycoside-inactivating enzymes compared with other aminoglycosides (1, 11) , whereas variations in the effects between the amikacin.--lactam combinations may be explained by the differences in the permeability of P-lactams through the bacterial outer cell membrane.
In vitro evaluation of the interactions between antibiotics are useful in selecting the most appropriate combination treatment in clinical practice. Consequently, the findings of i06. the present study may have important implications for treating patients infected with multiresista,nt P. aeruginosa strains.
